TRIUMPH-4 read-out: retatrutide hits 28.7% weight loss but a new dysesthesia signal complicates the path to filing

Key takeaways

• TRIUMPH-4, the first Phase 3 read-out of Eli Lilly's triple-receptor agonist retatrutide, reported 28.7% mean weight loss at the 12 mg dose and 26.4% at 9 mg, over 68 weeks in patients with obesity and knee osteoarthritis.
• A new dysesthesia signal — abnormal touch sensation — appeared at clinically meaningful frequency: 20.9% on 12 mg, 8.8% on 9 mg, against 0.7% on placebo. The signal was not seen in Phase 2.
• Seven further TRIUMPH Phase 3 trials are scheduled to read out across 2026, with TRIUMPH-1 (~2,500 obesity participants) expected Q2-Q3 and TRIUMPH-2 (obesity with type 2 diabetes, ~1,400 participants) expected Q3-Q4.
• An NDA filing is widely speculated for late 2026 or early 2027 but has not been confirmed by Lilly. Cardiovascular outcomes from TRIUMPH-CVOT are not due until 2028-2029.
• For procurement teams tracking the GLP-1 supply chain, the next four months will signal whether retatrutide displaces tirzepatide as the standard-of-care reference compound or arrives as a second-line option carrying a safety footnote.

For procurement teams watching the incretin-receptor agonist class, retatrutide has been the awaited fourth data point — after semaglutide, tirzepatide and orforglipron — to test whether triple-agonism delivers a step-change in obesity efficacy or merely an incremental gain at the cost of additional toxicity. The December 2025 TRIUMPH-4 read-out delivered both signals at once: the highest efficacy ever recorded in a Phase 3 obesity trial, and a new adverse-event signature that did not appear in Phase 2.

The practical question for the rest of 2026 is whether the dysesthesia finding holds, dilutes or worsens across the remaining seven Phase 3 trials.

TRIUMPH-4 in detail

TRIUMPH-4 enrolled 751 participants aged over 18 with a BMI of at least 27 kg/m² who met American College of Rheumatology criteria for knee osteoarthritis. Participants were randomised to retatrutide 9 mg, 12 mg, or placebo. According to coverage in Pharmaceutical Executive, the 12 mg arm achieved a mean 28.7% body-weight reduction at week 68, with 26.4% at 9 mg.

For context: the equivalent figure for tirzepatide in SURMOUNT-1 was approximately 22.5% at the top dose, and semaglutide in STEP 1 reached approximately 14.9%. A 28.7% Phase 3 result is the highest published number to date in the obesity class and, as Eli Lilly's investor communication noted, approaches outcomes seen with bariatric surgery.

The trial also reported meaningful symptomatic relief in the osteoarthritis comorbidity — a finding likely to be picked up by payers seeking to model the combined benefit of weight reduction and joint-pain reduction in older obese populations.

The dysesthesia signal

The more consequential read-out for medium-term commercial prospects may be the safety side. As BioSpace reported, TRIUMPH-4 revealed dysesthesia at frequencies that warrant attention: 20.9% on the 12 mg dose and 8.8% on the 9 mg dose, against 0.7% in the placebo arm. Dysesthesia in this context refers to abnormal touch perception — sensations that should be neutral are experienced as unusual or unpleasant.

Two aspects of the signal stand out. First, it was not reported in any Phase 2 data, which means it emerged at the longer exposure durations characteristic of Phase 3. Second, BioSpace notes that "the dysesthesia events did not seem to lead to discontinuation," suggesting the signal is tolerable rather than treatment-limiting in this cohort.

Whether that picture holds across more general obesity populations (TRIUMPH-1) and diabetic populations (TRIUMPH-2) will materially affect the label language and, by extension, prescribing patterns. Analysts cited by BioSpace flagged the signal as something they would be "watching for in read-outs to come."

What's coming across 2026

The full TRIUMPH programme comprises eight Phase 3 trials. Beyond TRIUMPH-4, six further read-outs are due during 2026:

• TRIUMPH-1 — general obesity, approximately 2,500 participants — expected Q2-Q3 2026.
• TRIUMPH-2 — obesity with type 2 diabetes, approximately 1,400 participants — expected Q3-Q4 2026.
• TRIUMPH-3 — obesity with obstructive sleep apnea, approximately 600 participants — late 2026.
• TRIUMPH-5 — weight maintenance, approximately 700 participants — timing unclear.
• TRIUMPH-EM — early-stage diabetes, approximately 1,000 participants over 104 weeks.
• TRIUMPH-NAFLD/NASH — liver disease, approximately 900 participants — timing unclear.

TRIUMPH-CVOT, the cardiovascular outcomes trial of approximately 10,000 participants, will not report until 2028-2029.

Third-party analysis suggests an NDA filing in Q4 2026 or Q1 2027 conditional on positive TRIUMPH-1 and TRIUMPH-2 results, but Lilly has not provided guidance on filing timing and procurement decisions should not assume the timetable.

Implications for the GLP-1 landscape

If the 28.7% efficacy bar holds across TRIUMPH-1 and TRIUMPH-2, and if the dysesthesia signal proves manageable, retatrutide is positioned to supplant tirzepatide as the reference Phase 3 result in the class. That outcome would have downstream effects on bulk-API demand patterns, contract-manufacturing capacity allocation, and pricing dynamics across the existing GLP-1 incumbents.

If either condition fails to hold, retatrutide may arrive as a second-line option for patients seeking outcomes beyond what tirzepatide delivers, with a label footnote on the sensory adverse-event profile. The commercial difference between those two outcomes is substantial.

What to watch

Three signals will matter most over the next nine months:

1. TRIUMPH-1 dysesthesia incidence — particularly the divergence between 9 mg and 12 mg doses, which will inform whether the maintenance-dose strategy (4 mg) can preserve efficacy while reducing the safety signal.
2. TRIUMPH-2 weight loss in diabetic populations — historically the GLP-1 class has shown reduced weight effect in T2DM cohorts. A retained 25%+ reduction in TRIUMPH-2 would be a stronger competitive signal than the headline TRIUMPH-4 figure.
3. Any Lilly guidance on regulatory timing — Q4 earnings calls (typically late October or early November) are the most likely venue for explicit NDA-filing commentary.

We will cover each TRIUMPH read-out as topline data emerges.